MSON - ミソニックス （MISONIX Inc.）

DURHAM, N.C., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, has completed the acquisition of Misonix, Inc. (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that are designed to enhance clinical outcomes, for cash and common stock. Pursuant to the terms of the merger agreement, Misonix has become a wholly owned subsidiary of Bioventus.

DURHAM, N.C. and FARMINGDALE, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) and Misonix, Inc . (Nasdaq: MSON) (Misonix), today announced an election deadline of 5:00 p.m., New York City Time, on October 25, 2021 (the Election Deadline) for stockholders of Misonix to elect the form of consideration they wish to receive for their shares of Misonix common stock in connection with the proposed merger of Oyster Merger Sub I, Inc., a newly-formed, wholly-owned subsidiary of Bioventus (Merger Sub I), with and into Misonix, immediately followed by the merger of Misonix with and into Oyster Merger Sub II, LLC, another newly-formed, wholly-owned subsidiary of Bioventus (Merger Sub II), pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated as of July 29, 2021, by and among Bioventus, Merger Sub I, Merger Sub II and Misonix (the Mergers). If the Election Deadline is delayed or extended for any reason, Bioventus and Misonix will promptly announce the delay and, when determined, the rescheduled Election Deadline.

The “Radiofrequency Ablation System Market” provides analysis and insights relating to the many factors expected to be rife throughout the forecast amount whereas providing their impacts on the Market’s growth. The increase within the aviation sector is escalating the expansion

NEW YORK , Oct. 4, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Misonix, Inc. (NASDAQ: MSON ) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Bioventus Inc. Under the terms of the agreement, Misonix stockholders may elect to receive either (i) 1.6839 shares of Bioventus class A common stock or (ii) $28.00 in cash, without interest, for each share of Misonix common stock they hold, subject to proration. If you are a Misonix shareholder, click here to learn more about your rights and options . Full story available on Benzinga.com

NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of Sanderson Farms, Inc. (NASDAQ: SAFM), Misonix, Inc. (NASDAQ: MSON), and Steadfast Apartment REIT, Inc. (Other OTC: STFR) (STAR). Additional information about each potential action can be found at the link provided.

DURHAM, N.C., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, has completed the acquisition of Misonix, Inc. (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that are designed to enhance clinical outcomes, for cash and common stock. Pursuant to the terms of the merger agreement, Misonix has become a wholly owned subsidiary of Bioventus.

DURHAM, N.C. and FARMINGDALE, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) and Misonix, Inc . (Nasdaq: MSON) (Misonix), today announced an election deadline of 5:00 p.m., New York City Time, on October 25, 2021 (the Election Deadline) for stockholders of Misonix to elect the form of consideration they wish to receive for their shares of Misonix common stock in connection with the proposed merger of Oyster Merger Sub I, Inc., a newly-formed, wholly-owned subsidiary of Bioventus (Merger Sub I), with and into Misonix, immediately followed by the merger of Misonix with and into Oyster Merger Sub II, LLC, another newly-formed, wholly-owned subsidiary of Bioventus (Merger Sub II), pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated as of July 29, 2021, by and among Bioventus, Merger Sub I, Merger Sub II and Misonix (the Mergers). If the Election Deadline is delayed or extended for any reason, Bioventus and Misonix will promptly announce the delay and, when determined, the rescheduled Election Deadline.

The “Radiofrequency Ablation System Market” provides analysis and insights relating to the many factors expected to be rife throughout the forecast amount whereas providing their impacts on the Market’s growth. The increase within the aviation sector is escalating the expansion

NEW YORK , Oct. 4, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Misonix, Inc. (NASDAQ: MSON ) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Bioventus Inc. Under the terms of the agreement, Misonix stockholders may elect to receive either (i) 1.6839 shares of Bioventus class A common stock or (ii) $28.00 in cash, without interest, for each share of Misonix common stock they hold, subject to proration. If you are a Misonix shareholder, click here to learn more about your rights and options . Full story available on Benzinga.com

NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of Sanderson Farms, Inc. (NASDAQ: SAFM), Misonix, Inc. (NASDAQ: MSON), and Steadfast Apartment REIT, Inc. (Other OTC: STFR) (STAR). Additional information about each potential action can be found at the link provided.

DURHAM, N.C., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, has completed the acquisition of Misonix, Inc. (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that are designed to enhance clinical outcomes, for cash and common stock. Pursuant to the terms of the merger agreement, Misonix has become a wholly owned subsidiary of Bioventus.

DURHAM, N.C. and FARMINGDALE, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) and Misonix, Inc . (Nasdaq: MSON) (Misonix), today announced an election deadline of 5:00 p.m., New York City Time, on October 25, 2021 (the Election Deadline) for stockholders of Misonix to elect the form of consideration they wish to receive for their shares of Misonix common stock in connection with the proposed merger of Oyster Merger Sub I, Inc., a newly-formed, wholly-owned subsidiary of Bioventus (Merger Sub I), with and into Misonix, immediately followed by the merger of Misonix with and into Oyster Merger Sub II, LLC, another newly-formed, wholly-owned subsidiary of Bioventus (Merger Sub II), pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated as of July 29, 2021, by and among Bioventus, Merger Sub I, Merger Sub II and Misonix (the Mergers). If the Election Deadline is delayed or extended for any reason, Bioventus and Misonix will promptly announce the delay and, when determined, the rescheduled Election Deadline.

The “Radiofrequency Ablation System Market” provides analysis and insights relating to the many factors expected to be rife throughout the forecast amount whereas providing their impacts on the Market’s growth. The increase within the aviation sector is escalating the expansion

NEW YORK , Oct. 4, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Misonix, Inc. (NASDAQ: MSON ) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Bioventus Inc. Under the terms of the agreement, Misonix stockholders may elect to receive either (i) 1.6839 shares of Bioventus class A common stock or (ii) $28.00 in cash, without interest, for each share of Misonix common stock they hold, subject to proration. If you are a Misonix shareholder, click here to learn more about your rights and options . Full story available on Benzinga.com

NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of Sanderson Farms, Inc. (NASDAQ: SAFM), Misonix, Inc. (NASDAQ: MSON), and Steadfast Apartment REIT, Inc. (Other OTC: STFR) (STAR). Additional information about each potential action can be found at the link provided.